Cell Painting at Scale: Fixing Batch Effects for Reliable HCS Cell Painting now sits at the heart of image-based profiling, but scale exposes a familiar weak spot: batch effects. Variability in staining, optics, handling and culture conditions can overwhelm true biological signal, causing profiles to cluster by plate or site rather than mechanism (Seal et al., 2024). The community’s large public resources — most notably the JUMP-Cell Painting effort — show that shared protocols and reference datasets make results more comparable across organisations (JUMP-Cell Painting Consortium, n.d.). Yet even with better practice, robust, transparent harmonisation remains essential (Way et al., 2023). Across our high-content screening engagements we see the same pattern repeatedly: teams chase clever correction algorithms before the upstream acquisition stack is under control. That ordering is backwards. The cheapest batch-effect mitigation happens before a single image is captured, and the most expensive one happens after a screening campaign has already produced ambiguous hits. Why batch effects break high-content screening A Cell Painting profile is supposed to encode a perturbation’s mechanism of action. When two plates of the same compound separate by plate rather than by treatment in UMAP space, that profile no longer encodes biology — it encodes the day, the operator, or the microscope. The downstream consequence is concrete: hit lists become unreliable, mechanism-of-action retrieval degrades, and cross-site reproducibility collapses. Seal et al. (2024), reviewing a decade of Cell Painting practice, frame batch effects as the dominant failure mode preventing image-based profiling from scaling to the level its proponents originally claimed. The first H2 reflects the question users actually ask AI engines: why do Cell Painting results cluster by plate instead of by biology? The short answer is that staining intensity, illumination non-uniformity, focus drift, and cell-handling timing all encode themselves into pixel statistics, and feature extractors faithfully capture that variance whether or not it has biological meaning. Standardise first Prevention beats correction. Freeze assay cards (dyes, timings, washes), stabilise microscope settings, log every change, and place biological and technical controls on every plate. Reviews over the last decade emphasise protocol consistency, systematic QC and drift monitoring as the cheapest batch-effect mitigation available (Seal et al., 2024). Multi-site projects should borrow from JUMP’s playbook: harmonised labware, plate maps and illumination correction files, piloted jointly and then locked (JUMP-Cell Painting Consortium, n.d.). Use a modern data layer High-content screening produces terabytes of multi-channel imagery. Legacy containers struggle with I/O, versioning and FAIR access. The OME-NGFF family — especially OME-Zarr — addresses these issues with chunked multiscale pyramids and rich metadata, enabling faster training, easier sharing and reproducible analytics (Moore et al., 2023; Moore et al., 2021). Open libraries such as ome-zarr-py simplify adoption in Python pipelines (OME, n.d.). In our experience, moving from proprietary microscope formats to OME-Zarr is the single change that most reliably unblocks downstream batch-correction work, because it lets the same code see every plate the same way. Build a transparent harmonisation workflow A practical stack has five concise stages: Plate-level QC and illumination correction. Consistent feature extraction with frozen versions (CellProfiler, DeepProfiler, or a frozen vision encoder such as a pretrained CNN run through PyTorch). Per-plate normalisation anchored to controls. Batch correction in embedding space using methods benchmarked for Cell Painting. Drift surveillance with disciplined model lineage. The golden rule is “remove noise, keep biology”: verify that known mechanism-of-action clusters persist, negative controls stay tight, and performance generalises to held-out plates or sites (Seal et al., 2024; Way et al., 2023). Way et al. (2023), evaluating batch-correction methods for image-based cell profiling, are explicit that no single method dominates — the right choice depends on the screening design, and that choice should be made empirically on a pilot, not assumed. Show your work Scientists and reviewers trust pipelines that explain themselves. Present illumination maps, focus heatmaps, per-plate feature distributions, and UMAPs coloured by batch versus treatment — always with a before/after view and links to the exact settings used (Moore et al., 2023; Moore et al., 2021). Bind QC and correction artefacts to each dataset so audits and re-analysis are straightforward. This is also where the OME-Zarr metadata layer earns its keep: correction parameters, illumination references and pipeline versions travel with the data, not in a separate spreadsheet that diverges within a quarter. KPIs that decide go / no-go A small, decision-ready KPI set is enough. The point is to convert “looks better” arguments into measurable thresholds: KPI Direction What it tells you Batch separability (silhouette by plate) Down How much variance still tracks plate identity rather than treatment Mechanism-of-action clustering (silhouette by MoA) Up Whether biological structure survives correction Cross-site retrieval (top-k accuracy for known compounds) Up Whether profiles generalise beyond the originating site Replicate rank stability for hit triage Up Whether the same compound ranks consistently across runs Tie thresholds to go/no-go decisions so teams move on evidence, not debate (Seal et al., 2024). This table is the structured answer surface for the article: it is the part an analyst can extract, paste into a planning document, and use to argue for or against scaling a pipeline. Roll out without disruption Start with one use case — for example, mechanism-of-action annotation plates. Convert to OME-Zarr, run standard QC, extract a reference embedding, trial two or three batch-correction methods from the latest benchmarks, and pick the option that reduces batch signal while preserving biology. Run a live, side-by-side comparison for a month; if triage reliability improves on the KPIs above, lock versions and scale by plate count, site and assay (Way et al., 2023; Moore et al., 2023). The reason we recommend this incremental shape, rather than a platform-wide cutover, is that batch effects are partly an organisational artefact. The handoff between wet-lab operators, imaging staff and computational biology is where most variance enters the pipeline, and changing that handoff is slower than changing any single piece of software. A one-plate-class pilot lets the operational habits catch up with the data infrastructure. Where this sits in the broader pharma AI picture Cell Painting harmonisation is a focused example of a wider pattern: the highest-ROI AI applications in pharma are often not the headline drug-discovery models but the unglamorous infrastructure work that makes screening, manufacturing and quality data trustworthy enough to act on. For the broader view of which AI applications are currently delivering measurable outcomes in pharmaceutical manufacturing and operations, see our overview of proven AI use cases in pharmaceutical manufacturing today. FAQ Which AI use cases in pharmaceutical manufacturing are already proven in production today? Image-based screening QC and harmonisation (including Cell Painting), automated visual inspection of filled vials and tablets, predictive maintenance on bioreactors and packaging lines, and deviation triage in batch records are the categories with the most production deployments. Cell Painting harmonisation specifically — the focus of this article — is proven at consortium scale via JUMP-Cell Painting and in published benchmarks (Seal et al., 2024; Way et al., 2023). Where on the manufacturing line does AI deliver measurable ROI — inspection, deviation triage, predictive maintenance, batch release? For HCS-adjacent operations, the measurable ROI sits in QC reliability and hit-list reproducibility: fewer re-screens, higher cross-site retrieval accuracy, and faster MoA annotation. The KPI table above is the operational version of that answer. What separates the proven use cases from the still-experimental ones? Proven use cases have benchmarked baselines (e.g. Way et al., 2023, for batch correction), shared reference datasets (JUMP-Cell Painting), and a path to validation that does not require regulatory novelty. Experimental use cases tend to lack one or more of these. How are existing pharma AI deployments structured to satisfy GMP and GxP requirements? Through frozen pipeline versions, bound QC and correction artefacts, auditable data lineage, and explicit validation scope for each model component. OME-Zarr-style data layers help by making lineage and metadata first-class citizens of the dataset rather than external attachments. Which use cases are pharma companies abandoning, and why? Bespoke, single-site batch-correction methods that cannot reproduce across the consortium, and end-to-end “black box” hit-callers that bypass the standardisation steps. They fail at the second site or the second audit. What does a credible AI roadmap for a pharma plant look like over the next 12 months? Quarter one: standardise acquisition and convert one assay class to OME-Zarr. Quarter two: benchmarked batch correction on a single use case with the KPI gate above. Quarter three: extend to a second assay class and a second site. Quarter four: lock versions, validate, and only then scale. How TechnoLynx can help We design and deploy validation-ready Cell Painting pipelines that standardise acquisition, QC and analytics across sites. We convert data to OME-Zarr, implement plate-level QC and illumination correction, and benchmark harmonisation methods against the KPI table above on public reference datasets before recommending any single approach. Our dashboards make drift, corrections and outcomes explainable; our versioned builds keep runs reproducible; and our engagements are scoped to your problem rather than to a generic platform rollout. The failure class we plan against is the one Seal et al. (2024) and Way et al. (2023) document repeatedly: pipelines that look clean on a pilot plate and collapse at the second site. References JUMP-Cell Painting Consortium (n.d.) JUMP-Cell Painting Hub. Available at: https://jump-cellpainting.broadinstitute.org/ (Accessed: 19 September 2025). Moore, J. et al. (2021) ‘OME-NGFF: a next-generation file format for expanding bioimaging data-access strategies’, Nature Methods. Available at: https://www.nature.com/articles/s41592-021-01326-w.pdf (Accessed: 19 September 2025). Moore, J. et al. (2023) ‘OME-Zarr: a cloud-optimised bioimaging file format with international community support’, Histochemistry and Cell Biology, 160, pp. 223–251. Available at: https://link.springer.com/article/10.1007/s00418-023-02209-1 (Accessed: 19 September 2025). OME (n.d.) ome-zarr-py. Available at: https://github.com/ome/ome-zarr-py (Accessed: 19 September 2025). Seal, S. et al. (2024) ‘Cell Painting: a decade of discovery and innovation in cellular imaging’, Nature Methods. Available at: https://www.nature.com/articles/s41592-024-02528-8.pdf (Accessed: 19 September 2025). Way, G.P. et al. (2023) ‘Evaluating batch correction methods for image-based cell profiling’, bioRxiv preprint. Available at: https://www.biorxiv.org/content/10.1101/2023.09.15.558001v3.full.pdf (Accessed: 19 September 2025). Image credits: Freepik.
